Silverarc Capital Management, LLC Zentalis Pharmaceuticals, Inc. Transaction History

Silverarc Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$66.92 - $84.79 $1.6 Million - $2.02 Million	-23,855 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$46.83 - $73.5 $509,042 - $798,945	-10,870 Reduced 31.3%	23,855 $1.59 Million
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $1.3 Million - $2.16 Million	34,725 New	34,725 $1.85 Million
Q1 2021 May 18, 2021	SELL	$35.69 - $52.72 $356,900 - $527,200	-10,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$31.71 - $57.97 $317,100 - $579,700	10,000 New	10,000 $519,000

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $170M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.